ALK and non-small cell lung carcinoma: Similarly, evidence also showed that NSCLC patients with TKI-related driver gene mutations often had poor ORR and PFS in anti-PD-1/PD-L1 treatment, in which the evidence for EGFR mutations and ALK fusions were strong, while other TKI-related driver gene mutations were not confirmed (46, 47).